Holistic Junction Explains Why Healing Arts and Massage Schools are Vital to the Medical Community

With over 2 million consumer hits monthly, and 13,000+ page views per day, Holistic Junction discovered crucial need for promoting Healing Arts and Massage Schools for several reasons. Opening doors for opportunity one student at a time, Holistic Junction believes in preserving fundamental health care portal to prospective students and future healthcare providers by creating a community-based site founded on principles of attaining overall wellbeing - mind, body and spirit. A holistic approach, Holistic Junction understands core values in achieving and maintaining a holistic lifestyle that provides essential nourishment for complete physical, mental and emotional health. Holistic Junction holds high regard to alternative medicine as it is comprised of a broad and unique spectrum of techniques, modalities and medical systems based on varying cultures and even ancient healing therapies. According to World Health Organization, alternative medicine (also known as 'traditional medicine') is increasing in use and popularity. In China alone, herbal preparations account for 30-50% of overall medicines. Additionally, in Europe, North America and other industrialized regions, over 50% of population have used complementary or alternative medicine. 158 Million Americans used complementary medicines in year 2000 itself. Overall, findings of World Health Organization also show that global market for herbal medicines presently generates over $60 Billion annually and is on rise.

Pfizer reacts with a Press Release, rather than a warning about strokes and heart attacks.

Want to know what Pfizer is saying about article linking its drug Bextra to strokes and heart attacks? Consider that Pfizer is selling $600,000,000 worth of drug, and then see what they have to say below. Pfizer Statement on Bextra(R) (Valdecoxib) Wednesday November 10, 1:55 pm ET

NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- Pfizer Inc said a New York Times article published today draws unsubstantiated conclusions about cardiovascular safety of its COX-2 medicine Bextra and is based on information that has not been published in a medical journal or subject to independent scientific review. In contrast, White et al. analysis published earlier this year in peer-reviewed American Journal of Therapeutics(1) stated that short-and intermediate-term treatment with Bextra was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients. This conclusion was based on evaluation of a clinical trials database that includes nearly 8,000 patients treated with Bextra for durations ranging from 6 to 52 weeks.

"Pfizer has shared Bextra clinical results in a timely manner with regulatory authorities both in United States and worldwide," said Joseph Feczko, MD, Pfizer's president of worldwide development. "In addition, in an October 15 communication, a comprehensive summary of currently available data was provided to healthcare professionals in United States." This communication included information regarding White analysis as well as results of studies in several surgical settings. As previously announced, Pfizer has committed to conducting further studies to confirm longer-term cardiovascular safety profile of Bextra in patients who require chronic treatment for arthritis with a COX-2-specific inhibitor.